Project Management and Coordination - Public Lead: VHIR

Objectives: To provide overall scientific direction and to drive the progress of the project, guiding the partners for the achievement of milestones and ensuring that work is undertaken with appropriate quality levels.

High Throughput Data Management - Public Lead: IMIDomics, SL

Objectives: To achieve an efficient and secure data management procedure from its origin to its storage and distribution among the other partners. To allow a cooperative data analysis environment following the FAIR Data Principles.

Patient Selection - Public Lead: VHIR

Objectives: To determine the clinical criteria of interest and select the patients that will be analysed using high-throughput technologies in WP4.

Molecular Data Generation from IMID biobank patients - Public Lead: CNAG

Objectives: To generate single-cell and bulk molecular data from biological samples from patients selected in WP3.

Systems Biology Analysis - Public Lead: KI

Objectives: To find novel combinations of drugs that are effective in more than one IMID, based on systems level modelling of immune responses and how they are affected by drugs.

Preclinical Validation of Combinatorial Therapies - Public Lead: IDIBAPS

Objectives: To evaluate the candidate combinatorial therapies across animal models of the different IMIDs. To test and compare de therapeutic efficacy and potential toxicity of combinatorial therapies vs. the approved monotherapies in animal models of various diseases.

Personalized Therapy Biomarker Development - Public Lead: IMIDomics, SL

Objectives: To identify a molecular pattern that efficiently captures the combinatorial treatment responder profile. To obtain a low-cost, informative method to predict the clinical response to the combinatorial therapy.

Clinical Study Validation of Combinatorial Therapies - Public Lead: CARDIFF AC

Objectives: To provide proof-of-principle validation of the efficacy of combinatorial therapy identified by WP6 in patients with different IMIDs.

Dissemination and Exploitation - Public Lead: VHIR

Objectives: To design a plan that allows for optimal information flow within the project and communication and dissemination of information and knowledge generated by the project to relevant stakeholders.

Ethics requirements - Public Lead: VHIR

Objectives: To define the ethics requirements the project must adhere to and to ensure compliance throughout its duration.

Project Packages

WP1. Project Management and Coordination – Public Lead: VHIR: Objectives: To provide overall scientific direction and to drive the progress of the project, guiding the partners for the achievement of milestones and ensuring that work is undertaken with appropriate quality levels.
WP2. High Throughput Data Management – Public Lead: IMIDomics, SL: Objectives: To achieve an efficient and secure data management procedure from its origin to its storage and distribution among the other partners. To allow a cooperative data analysis environment following the FAIR Data Principles.
WP3. Patient Selection – Public Lead: VHIR: Objectives: To determine the clinical criteria of interest and select the patients that will be analysed using high-throughput technologies in WP4.
WP4. Molecular Data Generation from IMID biobank patients – Public Lead: CNAG: Objectives: To generate single-cell and bulk molecular data from biological samples from patients selected in WP3.
WP5. Systems Biology Analysis – Public Lead: KI: Objectives: To find novel combinations of drugs that are effective in more than one IMID, based on systems level modelling of immune responses and how they are affected by drugs.
WP6. Preclinical Validation of Combinatorial Therapies – Public Lead: IDIBAPS: Objectives: To evaluate the candidate combinatorial therapies across animal models of the different IMIDs. To test and compare de therapeutic efficacy and potential toxicity of combinatorial therapies vs. the approved monotherapies in animal models of various diseases.
WP7. Personalized Therapy Biomarker Development – Public Lead: IMIDomics, SL: Objectives: To identify a molecular pattern that efficiently captures the combinatorial treatment responder profile. To obtain a low-cost, informative method to predict the clinical response to the combinatorial therapy.
WP8. Clinical Study Validation of Combinatorial Therapies – Public Lead: CARDIFF AC: Objectives: To provide proof-of-principle validation of the efficacy of combinatorial therapy identified by WP6 in patients with different IMIDs.
WP9. Dissemination and Exploitation – Public Lead: VHIR: Objectives: To design a plan that allows for optimal information flow within the project and communication and dissemination of information and knowledge generated by the project to relevant stakeholders.
WP10. Ethics requirements – Public Lead: VHIR: Objectives: To define the ethics requirements the project must adhere to and to ensure compliance throughout its duration.